Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC).

Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North S, Pouliot F, Rendon R, Shayegan B, Sridhar S, So A, Usmani N, Vigneault E, Chi KN.

Can Urol Assoc J. 2019 Jun 25. doi: 10.5489/cuaj.6136. [Epub ahead of print] No abstract available.

PMID:
31348741
2.

CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update.

Saad F, Hotte S, Catton C, Drachenberg D, Finelli A, Fleshner N, Gleave M, Kapoor A, Kassouf W, Loblaw A, North S, Usmani N, Chi KN.

Can Urol Assoc J. 2013 Jul-Aug;7(7-8):231-7. doi: 10.5489/cuaj.1542. No abstract available. Erratum in: Can Urol Assoc J. 2013 Sep;7(9-10):301.

3.

A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer.

Foroughi Moghadam MJ, Taheri S, Peiravian F.

Iran J Pharm Res. 2018 Winter;17(Suppl):17-37.

4.

The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).

Saad F, Chi KN, Finelli A, Hotte SJ, Izawa J, Kapoor A, Kassouf W, Loblaw A, North S, Rendon R, So A, Usmani N, Vigneault E, Fleshner NE.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):90-6. doi: 10.5489/cuaj.2526.

5.

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Kassouf W, Aprikian A, Black P, Kulkarni G, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Alam T, Brimo F, Blais N, Booth C, Chin J, Chung P, Drachenberg D, Fradet Y, Jewett M, Moore R, Morash C, Shayegan B, Gotto G, Fleshner N, Saad F, Siemens DR.

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E46-80. doi: 10.5489/cuaj.3583. Epub 2016 Feb 8. No abstract available.

6.

Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Kassouf W, Aprikian A, Saad F, Breau RH, Kulkarni G, Guttman DM, Bagshaw K, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Brimo F, Chung P, Drachenberg D, Fradet Y, Jacobsen N, Morash C, Shayegan B, Gotto G, Zlotta A, Fleshner N, Siemens DR, Black PC.

Can Urol Assoc J. 2018 Jul;12(7):E281-E297. doi: 10.5489/cuaj.5246. Epub 2018 Mar 19. No abstract available.

7.

Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.

Gómez-Caamaño A, González-San Segundo C, Henríquez I, Maldonado X, Zapatero A; Expert Panel for the Consensus on Management of Castration-Resistant Prostate Cancer 2017, Urological Tumours Working Group (URONCOR), Spanish Society of Radiation Oncology (SEOR).

Clin Transl Oncol. 2019 Apr;21(4):420-432. doi: 10.1007/s12094-018-1940-2. Epub 2018 Oct 6.

PMID:
30293231
8.

Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.

Hernandez RK, Cetin K, Pirolli M, Quigley J, Quach D, Smith P, Stryker S, Liede A.

Can J Urol. 2015 Aug;22(4):7858-64.

PMID:
26267023
9.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
10.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
11.

CUA-CUOG CRPC Guidelines: A useful compendium.

Chin JL.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E224-5. doi: 10.5489/cuaj.2873. No abstract available.

12.

[Recomendations on the management of controversies in advanced castrate-resistant prostate cancer].

Cózar JM, Solsona E, Morote J, Miñana B, Maroto JP, González Del Alba A, Climent MA, Carles J, Alcaraz A, Castellano D; Asociación Española de Urología; Grupo de Urología Oncológica; Grupo Español de Oncología Genitourinaria.

Actas Urol Esp. 2012 Nov-Dec;36(10):569-77. doi: 10.1016/j.acuro.2012.06.004. Epub 2012 Sep 19. Spanish.

PMID:
22999347
13.

Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.

Hao J, Ci X, Xue H, Wu R, Dong X, Choi SYC, He H, Wang Y, Zhang F, Qu S, Zhang F, Haegert AM, Gout PW, Zoubeidi A, Collins C, Gleave ME, Lin D, Wang Y.

Eur Urol. 2018 Jun;73(6):949-960. doi: 10.1016/j.eururo.2018.02.019. Epub 2018 Mar 12.

14.

Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience.

Afshar M, Evison F, James ND, Patel P.

Urol Oncol. 2015 Aug;33(8):338.e1-7. doi: 10.1016/j.urolonc.2015.05.003. Epub 2015 Jun 6.

PMID:
26059077
15.

Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.

Lee CH, Ku JY, Ha JM, Bae SS, Lee JZ, Kim CS, Ha HK.

Prostate. 2017 Jan;77(1):60-71. doi: 10.1002/pros.23248. Epub 2016 Aug 22.

PMID:
27550197
16.

Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.

Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW.

Cancer. 2013 Aug 15;119(16):2990-8. doi: 10.1002/cncr.28102. Epub 2013 May 29.

17.

Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer.

Sircar K, Huang H, Hu L, Liu Y, Dhillon J, Cogdell D, Aprikian A, Efstathiou E, Navone N, Troncoso P, Zhang W.

PLoS One. 2012;7(2):e31259. doi: 10.1371/journal.pone.0031259. Epub 2012 Feb 17.

18.
19.

Canadian guidelines for the management of benign prostatic hyperplasia.

Nickel JC, Herschorn S, Corcos J, Donnelly B, Drover D, Elhilali M, Goldenberg L, Grantmyre J, Laroche B, Norman R, Piercy B, Psooy K, Steinhoff G, Trachtenberg J, Saad F, Tanguay S; Canadian Prostate Health Council; Canadian Urological Association Guidelines Committee.

Can J Urol. 2005 Jun;12(3):2677-83.

PMID:
16011814
20.

Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.

Poon DM, Chan CK, Chan TW, Cheung FY, Kwong PW, Lee EK, Leung AK, Leung SY, Ma WK, So HS, Tam PC, Ho LY.

BJU Int. 2018 May;121(5):703-715. doi: 10.1111/bju.14091. Epub 2018 Jan 8.

Supplemental Content

Support Center